Skip to content
DataLookout
Menu

NCT07935889

Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Start date changed from estimate of Nov 10, 2026 to Nov 13, 2026
    • Study sites: 7 to 8
    • Primary and study completion dates: Nov 2, 2035 to Nov 30, 2035
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Overall survival (Cohort 1)
Timeframe: Up to 18 months
Overall survival (Cohort 2)
Timeframe: Up to 12 months

Secondary (4)

Incidence of grade 3+ central nervous system (CNS) toxicity, regardless of attribution (Overall CNS toxicity)
Incidence of grade 3+ higher CNS toxicity at least possibly attributable to radiation therapy (Treatment-related CNS toxicity)
Quality of life (Cohort 1) - EORTC QLQ-C30
Quality of life (Cohort 1) - EORTC QLQ-BN20

Arms and interventions

Arm A (dose-intensified radiation therapy)Experimental

Patients undergo thirty treatment fractions of dose-intensified proton or photon radiation therapy QD (Monday-Friday) over 6 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive SOC temozolomide during and/or after radiation therapy at the discretion of the treating team. Additionally, patients receive FET via injection or FDOPA IV and undergo PET/CT prior to treatment and optionally during treatment and follow-up. Patients also undergo MRI and blood sample collection throughout the study.

Arm B (standard radiation therapy)Active comparator

Patients undergo thirty treatment fractions of standard proton or photon radiation therapy QD (Monday-Friday) over 6 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive SOC temozolomide during and/or after radiation therapy at the discretion of the treating team. Additionally, patients receive FET via injection or FDOPA IV and undergo PET/CT prior to treatment and optionally during treatment and follow-up. Patients also undergo MRI and blood sample collection throughout the study.

Arm C (dose-intensified accelerated radiation therapy)Experimental

Patients undergo ten treatment fractions of dose-intensified accelerated proton or photon radiation therapy QD (Monday-Friday) over 2 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive SOC temozolomide during and/or after radiation therapy at the discretion of the treating team. Additionally, patients receive FET via injection or FDOPA IV and undergo PET/CT prior to treatment and optionally during treatment and follow-up. Patients also undergo MRI throughout the study.

Arm D (accelerated radiation therapy)Active comparator

Patients undergo ten treatment fractions of accelerated proton or photon radiation therapy QD (Monday-Friday) over 2 weeks in the absence of unacceptable toxicity. Patients may also receive SOC temozolomide during and/or after radiation therapy at the discretion of the treating team. Additionally, patients receive FET via injection or FDOPA IV and undergo PET/CT prior to treatment and optionally during treatment and follow-up. Patients also undergo MRI throughout the study.

Procedures: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography

Radiation: F-18 Fluoroethyltyrosine, Dose-intensified Photon Beam Radiation Therapy, Standard Photon Beam Radiation Therapy, Dose-intensified Accelerated Photon Beam Radiation Therapy, Accelerated Photon Beam Radiation Therapy, Proton Beam Radiation Therapy

Drugs: Fluorodopa F 18, Temozolomide

Other: Questionnaire Administration

Sites

8 sites in 1 country